CTOs on the Move

ParaPRO

www.parapro.com

 
ParaPRO is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.parapro.com
  • 11550 N Meridian St Ste 600
    Carmel, IN USA 46032
  • Phone: 317.428.4597

Executives

Name Title Contact Details

Similar Companies

The eNose Company

We want to produce and market early-warning systems for specific smells related to diseases, safety and well-being. We want to enhance the time and cost efficiency in diagnosing diseases through breath analysis and Microbe detection.

Aegis Therapeutics

Aegis Therapeutics LLC is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intercept Pharmaceuticals

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.

MIDi

MIDi is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.